Get the Stockscreener App
2.33
7.37%
0.16
Celularity Inc stock is traded at $2.33, with a volume of 78,198.
It is up +7.37% in the last 24 hours and up +49.84% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
See More
Previous Close:
$2.17
Open:
$2.14
24h Volume:
78,198
Relative Volume:
0.67
Market Cap:
$55.80M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-1.4866
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
+24.60%
1M Performance:
+49.84%
6M Performance:
-20.75%
1Y Performance:
-25.80%
1-Day Range:
$2.14
$2.33
1-Week Range:
$1.7001
$2.33
52-Week Range:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
2.33 | 44.79M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity (NASDAQ:CELU) Trading 7.4% Higher – Here’s Why - Defense World
Celularity extends debt maturity, issues stock to YA II PN By Investing.com - Investing.com India
Celularity extends debt maturity, issues stock to YA II PN - Investing.com
Celularity Extends Note Maturity with YA II PN - TipRanks
Celularity Inc. Advances Placental-Derived Therapies - TipRanks
Celularity (CELU) Reports Significant Revenue Growth in FY24 | C - GuruFocus
Celularity Announces Full Year 2024 Operating and Financial Results - The Manila Times
Celularity Inc. Reports Strong Financial Growth and Increased Revenue for Year Ended December 31, 2024 - Nasdaq
Celularity Inc SEC 10-K Report - TradingView
Nvidia (NVDA) Targets Trillion Dollar Opportunity as Trump Ponders Lifting AI Chip Curbs - The Globe and Mail
The end of La Niña: Lessons about Plains wheat drought & why spring weather is bearish for most grain markets - The Globe and Mail
Earnings To Watch: Caesars Entertainment (CZR) Reports Q1 Results Tomorrow - The Globe and Mail
Celularity (CELU) Resolves Nasdaq Fee Issue to Avoid Delisting | - GuruFocus
Celularity (NASDAQ:CELU) Stock Price Down 4.7% – Time to Sell? - Defense World
Celularity pays $70,000 fee to Nasdaq following receipt of notice - MSN
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - The Manila Times
Celularity Inc. Faces Potential Delisting from Nasdaq Due to Fee and Filing Delinquencies - Nasdaq
Celularity Given Until May 1 to Address Dual Nasdaq Compliance Issues or Face Delisting - Stock Titan
Celularity faces Nasdaq delisting over late filing By Investing.com - Investing.com India
Celularity faces Nasdaq delisting over late filing - Investing.com
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - The Manila Times
CMS Extends Medicare Coverage for Wound Care Products: Major Win for Skin Substitute Market - Stock Titan
Revolutionary NK Cell Therapy Shows Promise in Cancer Treatment: New Research Reveals - Stock Titan
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology - The Globe and Mail
Celularity Delays Yearly Report Filing Amid Financial Challenges - TipRanks
Celularity extends debt maturity, issues stock to investor By Investing.com - Investing.com Australia
Celularity enters into standby equity purchase agreement with Ya Ii Pn -March 21, 2025 at 04:39 pm EDT - MarketScreener
Celularity enters into standby equity purchase agreement with Ya Ii Pn - TradingView
Robust Growth in Regenerative Placental Cell Therapy Market - openPR.com
Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft - MSN
CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges - Investing.com Australia
CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges By Investing.com - Investing.com South Africa
Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing - Defense World
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - The Manila Times
Celularity Secures Crucial FDA Pathway for Wound Care ProductsCan They Capture Share of $810M Market? - StockTitan
Celularity inks manufacturing deal with BlueSphere Bio By Investing.com - Investing.com Australia
Celularity inks manufacturing deal with BlueSphere Bio - Investing.com
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - The Manila Times
Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential? - StockTitan
Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry - Simply Wall St
Celularity Inc. Extends Loan Agreements with Resorts World Inc and C.V. Starr & Co. - Defense World
SEC Form FWP filed by Celularity Inc. - Quantisnow
Celularity Inc (CELU) Stock: Analyzing the Market Value - The News Heater
Celularity Inc (CELU) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Placental Stem Cell Therapy Solution Market Size And Booming - openPR
Celularity files to sell 6.52M shares of Class A common stock, warrants - MSN
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):